Renal transplantation of 21 cases positive for HBsAg
10.3760/cma.j.issn.0254-1785.2009.03.011
- VernacularTitle:乙型肝炎表面抗原阳性患者肾移植21例
- Author:
Ronghua CAO
;
Junjie MA
- Publication Type:Journal Article
- Keywords:
Kidney transplantation;
Hepatitis B virus;
Infection
- From:
Chinese Journal of Organ Transplantation
2009;30(3):172-174
- CountryChina
- Language:Chinese
-
Abstract:
Objective To analyze the outcome of allograft function of the HBsAg(+) recipients and discuss the suitable time of antiviral therapy. Methods Twenty-one HBsAg(+) recipients were randomly divided two groups: one group (11 cases) taking lamivudine orally after recovery of intestinal function, and another group (10 cases) taking lamivudine orally when liver dysfunction and increased HBV-DNA (HBV-DNA>106 copies/L) occurred during the period of follow-up. Liver function, allograft function, and hepatitis virus reactivation were followed up for 2 years after transplantation. Results Hepatitis recurrence and liver dysfunction after renal transplantation lay in viral replication after immuno-suppression. Lamivudine therapy accomplished the goals of viral suppression, and normalization of alanine aminotransferase (ALT) levels. Preemptive lamivudine therapy for recipients had a better liver and allograft function than oral administration for patients with liver dysfunction and increased HBV-DNA copies during a period of the two-years follow-up. Conclusion HBsAg (+) is not contraindication of renal transplantation. Preemptive lamivudine therapy early after operation could avoid liver dysfunction and improve the renal allograft function during the period of two-years follow-up.
